Across TCGA pan-cancer cohorts, MT1A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MT1A data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MT1A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MT1A expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where MT1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.775	0.127	.003	32	view →
CCRCC	OS	Tertile	IV	0.173	1.000	.028	17	view →
LUAD	OS	Quartile	All	0.946	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MT1A tumor-vs-normal RNA expression · all MT1A data types